An observational study in Kidney Cancer, sponsored by SWOG Cancer Research Network. Completed. Per ClinicalTrials.gov, last updated 2014-02-25.
Sponsored by SWOG Cancer Research Network · Observational
RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment.
PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.
OBJECTIVES:
OUTLINE: This is a partially prospective, partially retrospective, multicenter, companion study.
Paraffin-embedded tumor tissue specimens from patients enrolled in SWOG-8949 are evaluated by cytogenetic analysis (e.g., presence of trisomy and loss of Y chromosome) and flow cytometric analysis (e.g., presence of nondiploid cells and presence of abnormal proliferation index).
PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
956 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.
This study's enrollment of 34 is below the median of 218 across 216 observational studies indexed under Kidney Neoplasms.
Browse Kidney Neoplasms studies →SWOG Cancer Research Network is the lead sponsor of 328 studies on the registry; 37 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
DISEASE CHARACTERISTICS:
Diagnosis of renal cell carcinoma
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Number of successes per number of evaluable samples
Success is defined as obtaining at least 10 analyzable metaphases.
Time frame: up to 4 years after registration
Number of abnormalities per number of successes
Abnormality is defined as at lease one clonal chromosomal abnormality.
Time frame: up to 4 years after registration
Correlation of tumor response to treatment with the type and number of abnormalities
Abnormality is defined as at lease one clonal chromosomal abnormality.
Time frame: up to 4 years after registration
Correlation of time from diagnosis to development of metastatic disease with the type and number of abnormalities
Abnormality is defined as at lease one clonal chromosomal abnormality.
Time frame: up to 4 years after registration
Correlation of time from first diagnosis of metastatic disease until death with the type and number of abnormalities
Abnormality is defined as at lease one clonal chromosomal abnormality.
Time frame: up to 4 years after registration
No study locations are listed for this record.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SWOG Cancer Research Network